AL-108 and AL-208, formulations of the neuroprotective NAP fragment of activity-dependent neuroprotective protein, for cognitive disorders.
Allon Therapeutics Inc is developing AL-108, an intranasally administered, eight-amino-acid peptide fragment (known as NAP) of activity-dependent neuroprotective protein, and AL-208, an intravenous formulation of NAP. AL-108 is undergoing phase II trials for cognitive impairment in Alzheimer's disease and schizophrenia. AL-108 is also being investigated as a neuroprotective agent, including for the treatment of Parkinson's disease and ocular disease. AL-208 is undergoing phase II clinical trials for the treatment of cognitive disorder and phase I clinical trials for ocular disease and cognitive deficits associated with coronary artery bypass graft or ischemia.
Geerts
Hugo
H
In Silico Biosciences Inc, 686 Westwind Drive, Berwyn, PA 19104, USA. Hugo-Geerts@In-Silico-Biosciences.com
D000818:Animals; D002986:Clinical Trials as Topic; D003072:Cognition Disorders / Q000188:drug therapy; D000075202:Contraindications; D004353:Drug Evaluation, Preclinical; D006801:Humans; D018696:Neuroprotective Agents / Q000009:adverse effects / Q000378:metabolism / Q000493:pharmacokinetics / Q000627:therapeutic use* / Q000633:toxicity; D009842:Oligopeptides / Q000009:adverse effects / Q000378:metabolism / Q000493:pharmacokinetics / Q000627:therapeutic use* / Q000633:toxicity; D010330:Patents as Topic; D012559:Schizophrenia / Q000188:drug therapy; D013329:Structure-Activity Relationship
D018696:Neuroprotective Agents; D009842:Oligopeptides; C425904:davunetide